Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia
2022; Elsevier BV; Volume: 242; Linguagem: Inglês
10.1016/j.clim.2022.109083
ISSN1521-7035
AutoresCaroline Plett, Lara Kristina Klauer, Daniel Christoph Amberger, Selda Ugur, Alexander Rabe, Zuzana Fischer, D. Deen, Annika Hirn-Lopez, Carina Gunsilius, Jan-Ole Werner, Jörg Schmohl, Doris Krämer, Andreas Rank, Christoph Schmid, Helga Schmetzer,
Tópico(s)Immune cells in cancer
Resumo(Leukaemia derived) dendritic cells (DC, DCleu) are potent stimulators of anti-leukaemic activity in acute myeloid leukaemia (AML) and can be generated with immunomodulatory kits containing granulocyte-macrophage-colony-stimulating-factor (GM-CSF), prostaglandin-E1 (PGE1), prostaglandin-E2 (PGE2) and/or picibanil (OK-321). Potential adverse effects initiated through kits, especially the proliferation of blasts, must be ruled out to ensure treatment safety. We quantified proliferating blasts with the proliferation markers CD71 and Ki-67 and the novel proliferation marker IPO-38 before and after kit treatment ex vivo. IPO-38 hereby appeared to be the most sensitive marker; a combination with CD71 may add value when assessing proliferation kinetics. Kit treatment did not or only slightly (<5%) induce blast proliferation in most cases. An induction of blast proliferation was only found in single cases and could be compensated by DCleu-induced anti-leukaemic activity in most times. Overall, we appraise kit treatment to be safe in vivo.
Referência(s)